Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia

被引：8

作者：

Kreuzer, Karl-Anton ^{[1
]}

Furman, Richard R. ^{[2
]}

Stilgenbauer, Stephan ^{[3
]}

Dubowy, Ronald L. ^{[4
]}

Kim, Yeonhee ^{[4
]}

Munugalavadla, Veerendra ^{[4
]}

Lilienweiss, Esther ^{[1
]}

Reinhardt, Hans Christian ^{[1
]}

Pettitt, Andrew R. ^{[5
]}

Hallek, Michael ^{[1
]}

机构：

[1] Univ Cologne, Dept Intern Med 1, Cologne, Germany

[2] Weill Cornell Med Coll, New York, NY USA

[3] Ulm Univ Med Ctr, Dept Intern Med 3, Ulm, Germany

[4] Gilead Sci Inc, Foster City, CA USA

[5] Univ Liverpool, Liverpool, Merseyside, England

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.192.192

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

192

引用

页数：6

共 50 条

[1] The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
Karl-Anton Kreuzer
Richard R. Furman
Stephan Stilgenbauer
Ronald L. Dubowy
Yeonhee Kim
Veerendra Munugalavadla
Esther Lilienweiss
Hans Christian Reinhardt
Paula Cramer
Barbara Eichhorst
Peter Hillmen
Susan M. O’Brien
Andrew R. Pettitt
Michael Hallek
Leukemia, 2020, 34 : 296 - 300
[2] The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
Kreuzer, Karl-Anton
Furman, Richard R.
Stilgenbauer, Stephan
Dubowy, Ronald L.
Kim, Yeonhee
Munugalavadla, Veerendra
Lilienweiss, Esther
Reinhardt, Hans Christian
Cramer, Paula
Eichhorst, Barbara
Hillmen, Peter
O'Brien, Susan M.
Pettitt, Andrew R.
Hallek, Michael
LEUKEMIA, 2020, 34 (01) : 296 - 300
[3] Improved overall survival of relapsed chronic lymphocytic leukemia (CLL) patients exhibiting a complex karyotype and treated with idelalisib plus rituximab
Kreuzer, Karl-Anton
Furman, Richard
Stilgenbauer, Stephan
Dubowy, Ronald
Kim, Yeonhee
Munugalavadla, Veerendra
Lilienweisz, Esther
Reinhardt, Hans Christian
Cramer, Paula
Eichhorst, Barbara
Hillmen, Peter
O'Brien, Susan
Pettitt, Andrew
Hallek, Michael
LEUKEMIA & LYMPHOMA, 2017, 58 : 167 - 168
[4] Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, Richard R.
Sharman, Jeff P.
Coutre, Steven E.
Cheson, Bruce D.
Pagel, John M.
Hillmen, Peter
Barrientos, Jacqueline C.
Zelenetz, Andrew D.
Kipps, Thomas J.
Flinn, Ian
Ghia, Paolo
Eradat, Herbert
Ervin, Thomas
Lamanna, Nicole
Coiffier, Bertrand
Pettitt, Andrew R.
Ma, Shuo
Stilgenbauer, Stephan
Cramer, Paula
Aiello, Maria
Johnson, Dave M.
Miller, Langdon L.
Li, Daniel
Jahn, Thomas M.
Dansey, Roger D.
Hallek, Michael
O'Brien, Susan M.
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (11): : 997 - 1007
[5] ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Ghia, Paolo
Pluta, Andrzej
Wach, Malgorzata
Lysak, Daniel
Kozak, Tomas
Simkovic, Martin
Kaplan, Polina
Kraychok, Iryna
Illes, Arpad
de la Serna, Javier
Dolan, Sean
Campbell, Phillip
Musuraca, Gerardo
Jacob, Abraham
Avery, Eric
Lee, Jae Hoon
Liang, Wei
Patel, Priti
Quah, Cheng
Jurczak, Wojciech
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (25) : 2849 - +
[6] Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia
Pagel, John M.
Coutre, Steven E.
Furman, Richard R.
Sharman, Jeff P.
Cheson, Bruce D.
Hillmen, Peter
Barrientos, Jacqueline C.
Zelenetz, Andrew D.
Kipps, Thomas J.
Flinn, Ian W.
Ghia, Paolo
Eradat, Herbert A.
Ervin, Thomas
Lamanna, Nicole
Coiffier, Bertrand
Pettitt, Andrew
Li, Xiaoming
Jahn, Thomas M.
O'Brien, Susan M.
Hallek, Michael J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S201 - S202
[7] Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Sharman, Jeff P.
Coutre, Steven E.
Furman, Richard R.
Cheson, Bruce D.
Pagel, John M.
Hillmen, Peter
Barrientos, Jacqueline C.
Zelenetz, Andrew D.
Kipps, Thomas J.
Flinn, Ian W.
Ghia, Paolo
Eradat, Herbert
Ervin, Thomas
Lamanna, Nicole
Coiffier, Bertrand
Pettitt, Andrew R.
Ma, Shuo
Tausch, Eugen
Cramer, Paula
Huang, Julie
Mitra, Siddhartha
Hallek, Michael
O'Brien, Susan M.
Stilgenbauer, Stephan
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (16) : 1391 - +
[8] ASCEND Phase 3 Study of Acalabrutinib vs Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 21 - 22
[9] A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
O'Brien, Susan M.
Lamanna, Nicole
Kipps, Thomas J.
Flinn, Ian
Zelenetz, Andrew D.
Burger, Jan A.
Keating, Michael
Mitra, Siddhartha
Holes, Leanne
Yu, Albert S.
Johnson, David M.
Miller, Langdon L.
Kim, Yeonhee
Dansey, Roger D.
Dubowy, Ronald L.
Coutre, Steven E.
BLOOD, 2015, 126 (25) : 2686 - 2694
[10] Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Coutre, Steven E.
Flinn, Ian W.
de Vos, Sven
Barrientos, Jacqueline C.
Schreeder, Marshall T.
Wagner-Johnson, Nina D.
Sharman, Jeff P.
Boyd, Thomas E.
Fowler, Nathan
Dreiling, Lyndah
Kim, Yeonhee
Mitra, Siddhartha
Rai, Kanti
Leonard, John P.
Furman, Richard R.
HEMASPHERE, 2018, 2 (03):

← 1 2 3 4 5 →